Cediranib drug page Clinical trials

Trials with Cediranib

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

7Trials
0Recruiting
23Countries
3.844Planned patients

Showing 1–7 of 7

Study of DNA Damage, Angiogenesis, and PD-L1 Inhibitors in Advanced Solid Tumors
Ongoing, not recruiting Phase 2 90 patients NCT03851614

This is a phase 2, single-centre, randomized, multi-cohort trial of subjects with advanced Mismatch Repair Proficient Colorectal Cancer (MMRp-CRC), Pancreatic Adenocarcinoma (PA), and Leiomyosarcoma (LMS). Subjects will be stratified based…

Canada Apr 2019 – Jan 2027 Interventional
Combined with: DurvalumabOlaparib
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Ongoing, not recruiting Phase 1 268 patients NCT02484404

Background: \- Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells. Cediranib is a drug that may stop the blood vessel growt…

United States Jun 2015 – Oct 2027 Interventional
Combined with: DurvalumabOlaparib
Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
Finished Phase 1 31 patients NCT01160926

To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.

United Kingdom Jul 2010 – Nov 2016 Interventional
Combined with: Selumetinib
A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX
Finished Phase 1 172 patients NCT00494221

This Study is in two parts, the first part is to make sure that combining a potential new treatment, cediranib (AZD2171), with a standard treatment (FOLFOX) for metastatic colorectal cancer is safe. Once this part is complete and it is dec…

Japan Jun 2007 – Aug 2012 Interventional
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Finished Phase 3 1.254 patients NCT00399035

The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colo…

Argentina, Australia, Brazil, Bulgaria and 7 more Nov 2006 – Aug 2016 Interventional
First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX
Finished Phase 2 1.814 patients NCT00384176

The purpose of this study is to see if Cediranib in combination with FOLFOX is effective in treating metastatic colorectal cancer and to see how it compares with Avastin (Bevacizumab) in combination with FOLFOX.

United States, Australia, Austria, Belgium and 7 more Aug 2006 – Aug 2015 Interventional
Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX)
Finished Phase 2 215 patients NCT00278889

The primary purpose of this study is to compare the efficacy of AZD2171 in combination with FOLFOX to the efficacy of bevacizumab in combination with FOLFOX, in the second-line treatment of patients with metastatic colorectal cancer

Austria, Belgium, Canada, Czechia and 5 more Jan 2006 – Oct 2009 Interventional